Dyadic Applied BioSolutions Signs OEM Distribution Deal With IBT Bioservices

• Dyadic Applied BioSolutions has entered an OEM distribution agreement with IBT Bioservices to commercialize recombinant protein products through IBT’s global sales channels. 

• Initial offerings include recombinant DNase I and transferrin for research-use-only applications, supporting the company’s shift toward product-based revenues. 

Dyadic Applied BioSolutions has entered into an original equipment manufacturer (OEM) distribution agreement with IBT Bioservices to commercialize its recombinant protein products. The agreement will enable Dyadic to distribute products through IBT’s established global sales channels, expanding market access and supporting its strategy to generate product-based revenue. 

The partnership covers recombinant proteins produced using Dyadic’s microbial expression platforms. Initial products expected under the agreement include recombinant DNase I and recombinant transferrin, with both human and bovine variants planned for research-use-only (RUO) applications. 

IBT Bioservices, a life sciences reagent manufacturer and distributor, provides access to global research markets and also offers preclinical CRO services. The collaboration allows Dyadic to leverage IBT’s commercial infrastructure to place products into the market while continuing to scale its manufacturing capabilities. 

According to the company, the agreement supports its transition from platform development to commercial execution and aligns with broader efforts to expand its recombinant protein portfolio across multiple end markets. The partnership also provides flexibility for potential future expansion, including supplying market-ready products or licensing production strains to partners. 

“It represents an important step in our transition from R&D-driven revenue toward commercial product sales.”

Joe Hazelton, President and Chief Operating Officer of Dyadic